COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I REGNREGN LY-CoVLY RemdesivirRMD
HCQ study #232 of 237
1/8 Late treatment study
Yegerov et al., medRxiv, doi:10.1101/2021.01.06.20249091 (Peer Reviewed)
Epidemiological and Clinical Characteristics, and Virologic Features of COVID-19 Patients in Kazakhstan: a Nation-Wide, Retrospective, Cohort Study
Source   PDF   Share   Tweet
Retrospective 1,072 hospitalized patients in Kazakhstan showing no mortality for HCQ treated patients, however only 23 patients received treatment - this result is not statistically significant.

Yegerov et al., 1/8/2021, retrospective, Kazakhstan, Asia, peer-reviewed, 8 authors.
risk of death, 95.3% lower, RR 0.05, p = 1.00, treatment 0 of 23 (0.0%), control 20 of 1049 (1.9%).
Details of all 237 studies    Meta analysis
Please send us corrections, updates, or comments.